Serina Therapeutics (SER) Retained Earnings (2017 - 2026)

Serina Therapeutics has disclosed Retained Earnings across 10 years of filings, most recently posting $95.5 million for Q2 2026.

• In Q2 2026, Retained Earnings rose 271.79% year-over-year to $95.5 million; the TTM figure through Jun 2026 stood at $95.5 million (up 271.79% YoY), while the FY2025 annual figure was -$63.5 million, down 241.24% from the prior year.
• Retained Earnings came in at $95.5 million for Q2 2026 at Serina Therapeutics, up from -$63.5 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $95.5 million in Q2 2026 to a low of -$127.6 million in Q3 2023.
• Average Retained Earnings over 5 years is -$57.2 million, with a median of -$60.2 million recorded in 2025.
• Year-over-year, Retained Earnings tumbled 241.24% in 2025 and jumped 271.79% in 2026.
• Over 5 years, Retained Earnings stood at -$116.2 million in 2022, then jumped by 71.45% to -$33.2 million in 2023, then soared by 235.51% to $45.0 million in 2024, then plunged by 241.24% to -$63.5 million in 2025, then jumped by 250.36% to $95.5 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $95.5 million in Q2 2026, -$63.5 million in Q4 2025, and -$60.2 million in Q3 2025.